Alan Kimura has been appointed chief medical officer of Cambridge, MA-based Enzyvant. Before joining Enzyvant, Kimura was chief medical officer of Foster City, CA-based SutroVax. His experience also includes posts at Shire (NASDAQ:SHPG), Novartis Vaccines, and Translate Bio (NASDAQ: TBIO). Enzyvant is the rare disease subsidiary of Switzerland-based Roivant Sciences. The company is preparing to file for FDA approval of RVT-802, a regenerative medicine therapy to treat complete DiGeorge anomaly, a rare disease in which babies are born without an organ called the thymus.